Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;25(1):56-67.
doi: 10.1111/dom.14843. Epub 2022 Sep 12.

Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents

Caroline E Geisler  1 , Meghan P Antonellis  2 , Wolfgang Trumbauer  1 , Jennifer A Martin  2 , Tamer Coskun  2 , Ricardo J Samms  2 , Matthew R Hayes  1
Affiliations

Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents

Caroline E Geisler et al. Diabetes Obes Metab. 2023 Jan.

Abstract

Aim: To investigate the role of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists alone or combined with glucagon-like peptide-1 receptor (GLP-1R) agonists to regulate palatable food intake and the role of specific macronutrients in these preferences.

Methods: To understand this regulation, we treated mice and rats on several choice diet paradigms of chow and a palatable food option with individual or dual GIPR and GLP-1R agonists.

Results: In mice, the dual agonist tirzepatide suppressed total caloric intake, while promoting the intake of chow over a high fat/sucrose diet. Surprisingly, GIPR agonism alone did not alter food choice. The food intake shift observed with tirzepatide in wild-type mice was completely absent in GLP-1R knockout mice, suggesting that GIPR signalling does not regulate food preference. Tirzepatide also selectively suppressed the intake of palatable food but not chow in a rat two-diet choice model. This suppression was specific to lipids, as GLP-1R agonist and dual agonist treatment in rats on a choice paradigm assessing individual palatable macronutrients robustly inhibited the intake of Crisco (lipid) without decreasing the intake of a sucrose (carbohydrate) solution.

Conclusions: Decreasing preference for high-caloric, high-fat foods is a powerful action of GLP-1R and dual GIPR/GLP-1R agonist therapeutics, which may contribute to the weight loss success of these drugs.

Keywords: diet preference; dual GIP/GLP-1 receptor agonists; food intake; obesity; tirzepatide.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests

No other potential conflicts of interest relevant to this article were reported.

Figures

Figure 1.
Figure 1.. Individual GIP and Dual GIP/GLP-1 Receptor Agonism on Choice Diet Preference between Chow and 40% High-Fat Diet (HFD) or Chow and 60% HFD for 5 Days in Mice.
Effect of once daily injections [vehicle, GIP-085, or tirzepatide (TZP)] on daily intake of choice between chow (A) and 40% HFD (B) and in a separate group of mice choice between chow (C) and 60% HFD (D). Five-day cumulative intake of chow (E), intake of HFD (F), and body weight change (G) for both choice experiments. Daily average intake of chow and HFD as Kcals (H) and as a percentage of total Kcal intake (I) for both choice experiments. For panels E-I, comparisons made within a choice experiment are indicated with letter sets (a,b or x,z) and comparisons of the same treatment between choice experiment are indicated by asterisks. N=6–8 per treatment group.
Figure 2.
Figure 2.. Chronic 14-day Dual GIP/GLP-1 Receptor Agonism on Choice Diet Preference between Chow and 60% High-Fat Diet (HFD) in Mice.
Effect of once daily injections [vehicle or tirzepatide (TZP)] on daily (A) and 14-day cumulative (B) chow intake, and daily (C) and 14-day cumulative (D) 60% HFD intake. 14-day cumulative weight change (E). Daily average intake of chow and 60% HFD as Kcals (F) and as a percentage of total Kcal intake (H). Direct comparisons are indicated with asterisks. N=5–6 per treatment group.
Figure 3.
Figure 3.. Tirzepatide Dose Response and Two-Choice Preference Intake in Diet-Induced Obese Rats.
Once daily tirzepatide injection dose response [vehicle or 0.3, 1, 3, 10, 30 nmol/kg tirzepatide (TZP)] on daily food intake (A), 15-day cumulative food intake (B), and body weight change (C). N=5 per treatment group. Effect of once daily injections [vehicle, tirzepatide (TZP), or sibutramine] on daily chow (D) and gubra diet (E) intake. 21-day cumulative chow intake (F), gubra diet intake (G), and weight change (H). Daily average intake of chow and gubra diet as Kcals (I) and as a percentage of total Kcal intake (J). Fat mass (K) and lean mass (L) as a percentage of body weight at baseline and week 3 of treatment. Direct comparisons are indicated with letter sets (a,b,c or x,y,z). For panels K-L, comparisons of the same treatment between timepoints are indicated by asterisks. N=8 per treatment group.
Figure 4.
Figure 4.. Individual or Combined GIP and GLP-1 Receptor Agonism on Choice Diet Preference between Chow, Crisco, Sucrose, and Water in Rats.
Effect of once daily IP injections [vehicle, GIP-085 (300nmol/kg), GLP-140 (100nmol/kg), or combined GIP-085/GLP-140 (Combo)] of daily (A) and 8-day cumulative (B) chow intake, daily (C) and 8-day cumulative (D) Crisco intake, daily (E) and 8-day cumulative (F) sucrose intake (10% solution), and daily (G) and 8-day cumulative (H) water intake. 8-day cumulative body weight change (I). Daily average intake of chow, sucrose, and Crisco as total Kcals (J), as a % of total Kcal intake (K), and the ratio of sucrose to Crisco Kcal intake (L). Direct comparisons are indicated with letter sets (a,b or x,z or m,n).
Figure 5.
Figure 5.. GLP-1 Receptor Knockout Eliminates Dual GIP/GLP-1 Receptor Agonism-Induced Preference Shift between 5-Day Choice Chow and 60% High-Fat Diet (HFD) in Mice.
Effect of once daily injections [vehicle or tirzepatide (TZP)] in wildtype (WT) and GLP-1 receptor knockout (KO) mice on daily intake of chow (A) and 60% HFD (B). Five-day cumulative intake of chow (C), intake of 60% HFD (D), and body weight change (E). Daily average intake of chow and 60% HFD as Kcals (F) and as a percentage of total Kcal intake (G). Direct comparisons are indicated with letter sets (a,b or x,z). N=4–6 per treatment group.
See this image and copyright information in PMC

References

    1. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. American journal of physiology Regulatory, integrative and comparative physiology. 2016;310(10):R885–895. - PMC - PubMed
    1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell metabolism. 2018;27(4):740–756. - PubMed
    1. Global diabetes therapeutic market has grown sixfold in last 20 years. GlobalData Pharma Intelligence Center 2021.
    1. Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. - PMC - PubMed
    1. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090. - PMC - PubMed